World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
73
Citations
17261
World Ranking
19693
National Ranking
791

Neuroscience

D-Index
73
Citations
17239
World Ranking
2222
National Ranking
83

Marco Onofrj publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Marco Onofrj sits on this spectrum.

38–47 publications: 18 scientists 48–57 publications: 79 scientists 58–67 publications: 193 scientists 68–77 publications: 323 scientists 78–87 publications: 406 scientists 88–97 publications: 452 scientists 98–107 publications: 539 scientists 108–117 publications: 505 scientists 118–127 publications: 522 scientists 128–137 publications: 469 scientists 138–147 publications: 456 scientists 148–157 publications: 459 scientists 158–167 publications: 397 scientists 168–177 publications: 383 scientists 178–187 publications: 350 scientists 188–197 publications: 302 scientists 198–207 publications: 306 scientists 208–217 publications: 262 scientists 218–227 publications: 242 scientists 228–237 publications: 220 scientists 238–247 publications: 203 scientists 248–257 publications: 174 scientists 258–267 publications: 176 scientists 268–277 publications: 175 scientists 278–287 publications: 125 scientists 288–297 publications: 116 scientists 298–307 publications: 127 scientists 308–317 publications: 128 scientists 318–327 publications: 99 scientists 328–337 publications: 89 scientists 338–347 publications: 78 scientists 348–357 publications: 96 scientists 358–367 publications: 66 scientists 368–377 publications: 59 scientists 378–387 publications: 65 scientists 388–397 publications: 54 scientists 398–407 publications: 48 scientists 408–417 publications: 49 scientists 418–427 publications: 34 scientists 428–437 publications: 31 scientists 438–447 publications: 30 scientists 448–457 publications: 31 scientists 458–467 publications: 36 scientists 468–477 publications: 40 scientists 478–487 publications: 35 scientists 488–497 publications: 30 scientists 498–507 publications: 23 scientists 508–517 publications: 26 scientists 518–527 publications: 20 scientists 528–537 publications: 23 scientists 538–547 publications: 20 scientists 548–557 publications: 20 scientists 558–567 publications: 17 scientists 568–577 publications: 14 scientists 578–587 publications: 20 scientists 588–597 publications: 20 scientists 598–607 publications: 19 scientists 608–617 publications: 18 scientists 618–627 publications: 17 scientists 628–637 publications: 11 scientists 638–647 publications: 11 scientists 648–657 publications: 11 scientists 658–667 publications: 8 scientists 668–677 publications: 7 scientists 678–687 publications: 11 scientists 688–697 publications: 10 scientists 698–707 publications: 4 scientists 708–717 publications: 6 scientists 718–727 publications: 5 scientists 728–737 publications: 5 scientists 738–747 publications: 9 scientists 748–757 publications: 9 scientists 758–767 publications: 3 scientists 768–777 publications: 7 scientists 778–787 publications: 7 scientists 788–797 publications: 6 scientists 798–807 publications: 2 scientists 808–817 publications: 2 scientists 818–827 publications: 7 scientists 828–837 publications: 0 scientists 838–847 publications: 9 scientists 848–857 publications: 3 scientists 858–867 publications: 1 scientists 868–877 publications: 3 scientists 878–886 publications: 6 scientists 887+ publications: 100 scientists
38 publications 887+

This scientist: 485 publications — 94th percentile

94% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 887 publications or more.

Marco Onofrj D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Marco Onofrj sits on this spectrum.

30–31 D-Index: 42 scientists 32–33 D-Index: 172 scientists 34–35 D-Index: 296 scientists 36–37 D-Index: 435 scientists 38–39 D-Index: 459 scientists 40–41 D-Index: 456 scientists 42–43 D-Index: 467 scientists 44–45 D-Index: 478 scientists 46–47 D-Index: 512 scientists 48–49 D-Index: 435 scientists 50–51 D-Index: 425 scientists 52–53 D-Index: 418 scientists 54–55 D-Index: 392 scientists 56–57 D-Index: 357 scientists 58–59 D-Index: 334 scientists 60–61 D-Index: 328 scientists 62–63 D-Index: 260 scientists 64–65 D-Index: 278 scientists 66–67 D-Index: 239 scientists 68–69 D-Index: 250 scientists 70–71 D-Index: 210 scientists 72–73 D-Index: 200 scientists 74–75 D-Index: 189 scientists 76–77 D-Index: 170 scientists 78–79 D-Index: 146 scientists 80–81 D-Index: 113 scientists 82–83 D-Index: 126 scientists 84–85 D-Index: 100 scientists 86–87 D-Index: 84 scientists 88–89 D-Index: 99 scientists 90–91 D-Index: 84 scientists 92–93 D-Index: 85 scientists 94–95 D-Index: 72 scientists 96–97 D-Index: 76 scientists 98–99 D-Index: 45 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 43 scientists 104–105 D-Index: 32 scientists 106–107 D-Index: 45 scientists 108–109 D-Index: 50 scientists 110–111 D-Index: 32 scientists 112–113 D-Index: 39 scientists 114–115 D-Index: 32 scientists 116–117 D-Index: 29 scientists 118–119 D-Index: 27 scientists 120–121 D-Index: 19 scientists 122–123 D-Index: 23 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 16 scientists 128–129 D-Index: 24 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 21 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 14 scientists 138–139 D-Index: 15 scientists 140–141 D-Index: 10 scientists 142–143 D-Index: 10 scientists 144–145 D-Index: 13 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 8 scientists 150–151 D-Index: 6 scientists 152–153 D-Index: 6 scientists 154–155 D-Index: 7 scientists 156–157 D-Index: 7 scientists 158–159 D-Index: 10 scientists 160–161 D-Index: 4 scientists 162 D-Index: 8 scientists 163+ D-Index: 100 scientists
30 D-Index 163+

This scientist: 73 D-Index — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 163 D-Index or more.

Overview

Marco Onofrj is affiliated with the University of Chieti-Pescara in Italy. The research profile covers extensive work in the fields of Medicine and Neuroscience, with a particular focus on Neurology, Cognitive Neuroscience, Psychiatry and Mental Health, Pathology and Forensic Medicine, and Rheumatology. Their research contributions include 327 publications in Medicine and 95 in Neuroscience, reflecting a broad expertise across these scientific disciplines.

The main topics of study addressed by Marco Onofrj include:

  • Multiple Sclerosis Research Studies
  • EEG and Brain-Computer Interfaces
  • Functional Brain Connectivity Studies
  • Epilepsy research and treatment
  • Long-Term Effects of COVID-19
  • Rheumatoid Arthritis Research and Therapies
  • Neurological disorders and treatments

Frequent publication venues identify key platforms for their scientific output. These venues include:

  • Journal of the Neurological Sciences
  • Neurological Sciences
  • Neurology
  • Journal of Neurology Neurosurgery & Psychiatry
  • Frontiers in Neurology

Marco Onofrj has collaborated with several recurrent co-authors in their research, illustrating a network of scientific partnerships. Prominent co-authors are:

  • Stefano L. Sensi
  • Mirella Russo
  • Laura Bonanni
  • Fedele Dono
  • Francesco Patti

Important recent publications demonstrate the scope and topics of their research. Selected papers include:

  • "Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel," 2021, Alzheimer s & Dementia
  • "GBA-Related Parkinson's Disease: Dissection of Genotype-Phenotype Correlates in a Large Italian Cohort," 2020, Movement Disorders
  • "Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions," 2021, Frontiers in Neurology
  • "Progression is independent of relapse activity in early multiple sclerosis: a real-life cohort study," 2022, Brain
  • "Visual hallucinations in neurological and ophthalmological disease: pathophysiology and management," 2020, Journal of Neurology Neurosurgery & Psychiatry

Best Publications

  • Peripheral cytokines profile in Parkinson's disease

    M. Reale;C. Iarlori;A. Thomas;D. Gambi

  • EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up

    Laura Bonanni;Astrid Thomas;Pietro Tiraboschi;Bernardo Perfetti

  • A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule

    Bengt Winblad;Jeffrey Cummings;Niels Andreasen;George Grossberg

  • Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations.

    Rupam Borgohain;J. Szasz;P. Stanzione;C. Meshram

  • Cerebrospinal fluid lysosomal enzymes and alpha-synuclein in Parkinson's disease.

    Lucilla Parnetti;Davide Chiasserini;Emanuele Persichetti;Paolo Eusebi

  • Duration of amantadine benefit on dyskinesia of severe Parkinson’s disease

    A Thomas;D Iacono;A L Luciano;K Armellino

  • What electrophysiology tells us about Alzheimer's disease: a window into the synchronization and connectivity of brain neurons.

    Claudio Babiloni;Katarzyna Blinowska;Laura Bonanni;Andrej Cichocki

  • Preladenant in patients with Parkinson's disease and motor fluctuations: a phase 2, double-blind, randomised trial

    Robert A Hauser;Marc Cantillon;Marc Cantillon;Emmanuelle Pourcher;Federico Micheli

  • Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease.

    Alessio Di Fonzo;Alessio Di Fonzo;Cristina Tassorelli;Michele De Mari;Hsin F Chien

  • Pathological gambling in Parkinson disease is reduced by amantadine

    Astrid Thomas;Laura Bonanni;Francesco Gambi;Angelo Di Iorio

  • Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias†‡

    Lucilla Parnetti;Davide Chiasserini;Gianni Bellomo;David Giannandrea

  • Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel

    Claudio Babiloni;Xianghong Arakaki;Hamed Azami;Karim Bennys

  • Agomelatine versus venlafaxine XR in the treatment of anhedonia in major depressive disorder: a pilot study.

    Giovanni Martinotti;Gianna Sepede;Francesco Gambi;Giuseppe Di Iorio

  • Proteomics characterization of extracellular vesicles sorted by flow cytometry reveals a disease-specific molecular cross-talk from cerebrospinal fluid and tears in multiple sclerosis.

    Damiana Pieragostino;Paola Lanuti;Ilaria Cicalini;Maria Concetta Cufaro

  • Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up.

    M. Onofrj;A. Thomas;G. D'Andreamatteo;D. Iacono

  • Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism

    M. Onofrj;A.L. Luciano;A. Thomas;D. Iacono

  • Rotigotine and specific non-motor symptoms of Parkinson's disease: post hoc analysis of RECOVER.

    K. Ray Chaudhuri;Pablo Martinez-Martin;Angelo Antonini;Richard G. Brown

  • Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study.

    Werner Poewe;Erik Wolters;Murat Emre;Marco Onofrj

  • LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study

    Marialuisa Quadri;Wim Mandemakers;Martyna M. Grochowska;Roy Masius

  • Early DEtection of wEaring off in Parkinson disease: the DEEP study.

    F Stocchi;A Antonini;P Barone;M Tinazzi

  • A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients†‡§

    Fabrizio Stocchi;Rupam Borgohain;Marco Onofrj;Anthony H.V. Schapira

  • Visual evoked potentials in parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans.

    M Onofrj;M F Ghilardi;M Basciani;D Gambi

  • Botulinum toxin treatment of lateral axial dystonia in Parkinsonism.

    Laura Bonanni;Astrid Thomas;Sara Varanese;Vincenzo Scorrano

  • Quantitative electroencephalogram utility in predicting conversion of mild cognitive impairment to dementia with Lewy bodies

    Laura Bonanni;Bernardo Perfetti;Stefania Bifolchetti;John Paul Taylor

  • Improvement of motor function in early Parkinson disease by safinamide

    F. Stocchi;G. Arnold;M. Onofrj;H. Kwiecinski

Frequent Co-Authors

Laura Bonanni
Laura Bonanni University of Chieti-Pescara
Raffaella Franciotti
Raffaella Franciotti University of Chieti-Pescara
Fabrizio Stocchi
Fabrizio Stocchi San Raffaele University of Rome
John-Paul Taylor
John-Paul Taylor Newcastle University
Helmut Butzkueven
Helmut Butzkueven Monash University
Maria Trojano
Maria Trojano University of Bari Aldo Moro
Flavio Nobili
Flavio Nobili University of Genoa
Eva Havrdova
Eva Havrdova Charles University
Alexandre Prat
Alexandre Prat University of Montreal
Ivan Bodis-Wollner
Ivan Bodis-Wollner SUNY Downstate Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Marco Onofrj

Trending Scientists